KRAS and non-small cell lung carcinoma: K‐Ras mutation accounts for roughly 25% of NSCLC;25 however, K‐Ras cannot be directly targeted for treatment.9 Hence, targeting downstream K‐Ras substrates may represent to be a more feasible approach.